- Specialty
-
Onco-hepatology (hepatocellular carcinoma, cholangiocarcinoma, rare liver cancers)
- Hospital
-
Hôpital Beaujon (Clichy)
- Latest articles
-
-
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
(Sep 1, 2026)
-
Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).
(Aug 6, 2026)
-
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.
(Aug 1, 2026)
-
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.
(Aug 1, 2026)
-
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study.
(Jul 6, 2026)
